Literature DB >> 8119326

Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats.

M Törnwall1, P T Männistö.   

Abstract

The effects of three new, selective inhibitors of catechol O-methylation were compared regarding their potentiation of L-3,4-dihydroxyphenylalanine (L-dopa)/carbidopa-induced contralateral circling behaviour in male rats. Some studies were also done with amphetamine, which causes ipsilateral turning. A peripherally acting compound, entacapone, a peripherally and centrally acting compound, tolcapone, and an atypical compound, CGP 28014 (3, 10 or 30 mg/kg) increased the effect of L-dopa/carbidopa (2/30 or 5/30 mg/kg) on contralateral circling by 2.0-6.1-fold. Addition of clorgyline (3 mg/kg) did not increase, but rather decreased, the entacapone (3 mg/kg) and L-dopa/carbidopa (2/30 or 5/30 mg/kg)-induced peak circling. Amphetamine (2.5 mg/kg)-induced ipsilateral circling behaviour was not affected by tolcapone (30 mg/kg). We conclude that L-dopa-induced circling behaviour is enhanced and prolonged by all types of catechol O-methyltransferase inhibitors regardless of their brain penetration. The results suggest that catechol O-methylation inhibitors may be beneficial as L-dopa adjuncts in the treatment of patients with Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8119326     DOI: 10.1016/0014-2999(93)90623-p

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Inhibitors of catechol-O-methyltransferase sensitize mice to pain.

Authors:  O Kambur; R Talka; O B Ansah; V K Kontinen; A Pertovaara; E Kalso; P T Männistö
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

2.  Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone.

Authors:  T Keränen; A Gordin; M Karlsson; K Korpela; P J Pentikäinen; H Rita; E Schultz; L Seppälä; T Wikberg
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

3.  Clinical Potential of Catechol-OMethyltransferase (COMT) Inhibitors as Adjuvants in Parkinson's Disease.

Authors:  P T Ménnistó
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

4.  D-amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice.

Authors:  Marko Huotari; J Arturo García-Horsman; Maria Karayiorgou; Joseph A Gogos; Pekka T Männistö
Journal:  Psychopharmacology (Berl)       Date:  2003-10-23       Impact factor: 4.530

Review 5.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Authors:  Susan Duty; Peter Jenner
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

6.  Mesocorticolimbic monoamine correlates of methamphetamine sensitization and motivation.

Authors:  Kevin D Lominac; Courtney L McKenna; Lisa M Schwartz; Paige N Ruiz; Melissa G Wroten; Bailey W Miller; John J Holloway; Katherine O Travis; Ganesh Rajasekar; Dan Maliniak; Andrew B Thompson; Lawrence E Urman; Tamara J Phillips; Karen K Szumlinski
Journal:  Front Syst Neurosci       Date:  2014-05-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.